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Summary Acquired resistance to cisplatin (DDP) is a major clinical problem in the treatment of ovarian,
testicular, and head and neck carcinomas; decreased accumulation of DDP is the most consistently observed
alteration in resistant cells. It has been postulated that DDP enters the cell by passive diffusion based on the
observations that DDP accumulation is proportional to the drug concentration, accumulation is not saturable,
and that structural analogs of DDP do not inhibit accumulation. However, recent studies show that DDP
accumulation can be specifically stimulated or inhibited by pharmacological agents and the activation of signal
transduction pathways. This paper reviews the existing data on the mechanism of DDP accumulation and
develops the postulate that some component of transport occurs through a gated ion channel.
Cisplatin (DDP) is one of the most effective drugs used in
treatment of ovarian, testicular, and head and neck car-
cinomas. However, these tumours characteristically develop
resistance to DDP during therapy and this resistance
accounts for treatment failure. At present the dominant
mechanism accounting for clinically acquired resistance is
unknown. Resistance in cell lines generated by super-
pharmacological concentrations of DDP is multifactorial.
Four biochemical alterations have been reported to be
capable of producing DDP resistance including: (1) decreased
cellular accumulation of DDP; (2) increased levels of
glutathione (GSH) or of glutathione-S-transferase activity;
(3) increased levels of intracellular metallothioneins (MTs);
and (4) enhanced DNA repair (Andrews & Howell, 1990;
Kelley & Rozencweig, 1989; Perez et al., 1990; Timmer-
Bosscha et al., 1992). While the significance or generality of
any one of these mechanisms has not been rigorously estab-
lished, various investigators have demonstrated a correlation
between drug accumulation and sensitivity. In the majority of
cases, resistant sublines accumulated less DDP than the drug-
sensitive line from which they were derived (reviewed in
Andrews and Howell, 1990). Decreased DDP accumulation
develops early during the selection of resistant cells both in
vitro and in vivo (Andrews et al., 1990). Despite its apparent
importance to the resistant phenotype, the mechanism by
which DDP enters the cell, and the alteration which causes
decreased accumulation in resistant cells, remains unknown.
Although there are a large number of pharmacologic agents
which are able to modify DDP toxicity (reviewed in the
above references), this review will concentrate on those that
have effects on DDP accumulation.
Arguments for passive diffusion
It has been generally supposed that DDP enters the cell
largely through passive diffusion. Gale et al. found that a
double reciprocal (Lineweaver-Burk) plot of platinum
accumulation vs drug concentration yielded a straight line
through the origin, indicating that the rate limiting factor for
platinum uptake was the concentration of the drug (Gale et
al., 1973). Binks and Dobrota also found that the uptake of
platinum into everted rat intestine was described by a double
reciprocal plot that intersected the origin (Binks & Dobrota,
1990).
In another paper, Ogawa et al. observed that the fraction
of murine cells surviving a one hour exposure to DDP in-
creased only from 5% at 37°C to 35% at 4°C (Ogawa et al.,
1975). In contrast, at an equitoxic dose, the cytotoxicity of
nitrogen mustard was abolished at 4°C. They postulated that
the lack ofcell death in the case ofnitrogen mustard was due
to inactivation of a transporter at low temperature. Since this
effect was not observed for DDP, they concluded that there
was no DDP transporter.
A strong argument against the hypothesis that there is an
active transporter for DDP is that the accumulation is not
inhibited by structural analogs (Andrews et al., 1987;
Andrews, 1991). Andrews et al. measured the uptake of
'95Pt-DDP into human ovarian carcinoma 2008 cells in the
presence of excess trans-DDP, carboplatinum, DACH-Pt,
and cis-diamminedichloropalladium(II) (cis-PdCI2(NH3))
(Andrews et al., 1987; Andrews, 1991). The only compound
that inhibited DDP accumulation was cis-PdCl2(NH3). How-
ever, even this analog produced only 5% inhibition that was
attributed to non-specific damage from the highly reactive
drug.
Perhaps the most compelling argument against DDP enter-
ing the cell through an active mechanism is that the uptake
of DDP is not saturable. Gale et al. found that the uptake of
a tritiated platinum compound, cis-diammine(dipyridine)
platinum(II), into Ehrlich ascites tumour cells was linear up
to the levels of its solubility in DMSO (Gale et al., 1973).
This observation has been subsequently confirmed by other
groups by measuring the cellular uptake of DDP using either
atomic absorption or '95Pt-DDP. Hromas et al. found that
the uptake of '95Pt-DDP into sensitive and resistant murine
L1210 cells was linear up to 100 1M (Hromas et al., 1987).
Mann et al. showed that the uptake of DDP into sensitive
and resistant 2008 cells was linear up to 3.33 mM, the limit of
its solubility in saline (Mann et al., 1990).
Arguments for protein-mediated transport
Despite the above observations, there is an increasing body
of data suggesting that some component of DDP uptake
must be mediated by a form of transport mechanism. As
early as 1981, Byfield and Calabro-Jones postulated that
DDP may be entering the cell via a carrier mediated process
(Byfield & Calabro-Jones, 1981). They based their hypothesis
on the observation that DDP showed differential toxicity in
cycling and resting human T lymphocytes, a pattern shared
by alkylating agents with known carriers (melphalan and
nitrogen mustard) but not observed in agents that enter the
cell through passive diffusion (mitomycin C and various nit-
rosoureas).
In 1984, Dornish et al. found that the protein synthesis
inhibitor benzaldehyde reduced the cytotoxicity of DDP in
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human NHIK 3025 cells, but had no effect on the cytotoxi-
city of 1,3-bis(2-chloroethyl)-l-nitrosourea or nitrogen mus-
tard (Dornish et al., 1984). They also found that another
inhibitor of protein synthesis, cycloheximide, did not have
the same effect. To determine if the benzene ring was respon-
sible for these observed effects, they also tested benzoic acid
and benzyl alcohol. These benzene derivatives did not have
any effect on DDP toxicity and they postulated that the
benzaldehyde was reacting with membrane proteins to inhibit
the uptake of DDP.
Dornish and Pettersen later observed that the aldehyde
derivatives pyridoxal and pyridoxal-5-phosphate are also able
to protect NHIK 3025 cells from DDP toxicity (Dornish &
Pettersen, 1985). Further study suggested that these
aldehydes form Schiff bases with amino groups on the cell
surface. This theory was confirmed by measuring the shift in
absorbance maximums of these aldehydes from 388 to
315 nm (Dornish & Pettersen, 1985). Since pyridoxal-5-
phosphate is cell membrane impermeable, yet still protects
cells from DDP toxicity, they concluded that these aldehydes
exert their protective effects by interacting with something
exposed on the extracellular surface of the cell. In 1986, they
were able to confirm, by atomic absorption, that benzalde-
hyde and the other aldehydes protect cells by inhibiting the
uptake of DDP by 50% (Dornish et al., 1986). More
recently, this group has determined that a large number of
aldehyde compounds inhibit the uptake of DDP, presumably
by forming Schiff bases with membrane proteins (Dornish et
al., 1989). It should be noted that the maximum inhibition of
DDP uptake by any of these compounds was 50%.
In another group of experiments, this group has found that
the mitotic inhibitor l-propargyl-5-chloropyrimidin-2-one
(NY 3170) synergistically enhances DDP toxicity (Dornish et
al., 1987). This effect is mediated through an increase in
DDP accumulation. When NHIK 3025 cells were treated
concurrently with DDP and 2 mM NY 3170, DDP accumula-
tion at 1 and 2 h increased 2-fold as measured by atomic
absorption. At present the mechanism of this increase in
uptake is unknown.
Morikage et al. found that DDP resistance in a non-small
cell lung cancer could be reversed by the macrolide polyene
antibiotic amphotericin B (AmB) (Morikage et al., 1991). A
3 h preincubation with AmB increased DDP accumulation in
the resistant cells to that of the parental DDP-sensitive line.
AmB had no effect on the accumulation in the sensitive line.
Although AmB has been reported to form aqueous channels
in the cell membrane, Morikage et al. were unable to deter-
mine why AmB had effects on the resistant cells, but not on
the sensitive parental cell line.
In 1988, Andrews et al. observed that the DDP-resistant
2008/C13*5.25 cells, derived from the human ovarian 2008
cell line, accumulated 50% less DDP at one hour than the
parental cell line (Andrews et al., 1988). In order to deter-
mine if the decreased uptake could be explained by a change
in the plasma membrane, Mann et al. studied the lipid
composition and membrane fluidity of the sensitive and resis-
tant cell lines (Mann et al., 1988). Although there were slight
differences in the lipid compositions of the cells, the resultant
membrane fluidity was not significantly different in the sensi-
tive and resistant cells when determined by direct measure-
ment of fluorescence polarisation.
To further study the decreased accumulation by the resist-
ant cells, uptake was measured in the presence of metabolic
inhibitors (dinitrophenol, sodium fluoride, and iodoacetate)
and the sodium-potassium ATPase inhibitor ouabain (And-
rews et al., 1988). None of the metabolic inhibitors inhibited
DDP uptake when added individually (iodoacetate actually
increased uptake, probably through disruption of the cell
membrane), but when added in combination, uptake was
inhibited by 45%.
The sodium-potassium ATPase inhibitor ouabain inhibited
uptake by 25% when cells were exposed to Louabain at a
concentration of 0.2mM for 30min (Andrews et al., 1988).
In a later paper, Andrews et al. determined that longer
pre-incubation (1 h) with ouabain increased the inhibition of
uptake to 50% (Andrews et al., 1991). In order to determine
if the effect of ouabain was on the transport of DDP into the
cell, and not an effect on metabolism or efflux, short term
uptake of '95Pt-DDP was measured. Ouabain inhibited
uptake at time points as early as 1 min. When the ATPase
was inactivated by replacing the sodium in the media with
choline, or by decreasing the extracellular levels of potas-
sium, DDP uptake was also inhibited by 50% at these early
time points. Recently, Andrews et al. demonstrated that the
sodium/potassium ATPase itself was not directly transporting
DDP. By increasing intracellular sodium with the sodium
ionophore, monensin, they were able to increase the activity
of the ATPase by 160%. However, DDP accumulation was
unchanged (Andrews & Albright, 1991). Andrews et al. have
also demonstrated that DDP accumulation is potassium
dependent, and therefore also appears to be dependent on
the membrane potential. When the membrane was depolarised
by incubation in high potassium media, the cells accumulated
5.4-fold more DDP in 10 min than did the control cells
(Andrews & Albright, 1991). They also found that two DDP-
resistant sublines, 2008/C13*5.25 and A2780/CP, had
elevated membrane potential, suggesting that DDP-
accumulation appears to be inversely related to membrane
potential. These findings suggest that some component of
DDP accumulation is via a process that is dependent upon
the cell maintaining an electrochemical gradient across the
membrane.
The uptake of DDP has also been shown to be inhibited
by the overexpression of the c-Ha-ras oncogene (Isonishi et
al., 1991). Isonishi et al. created an NIH3T3 cell line stabily
transfected with the c-Ha-ras oncogene gene under the con-
trol of the mouse mammary tumour virus promoter. When
c-Ha-ras expression was induced with dexamethasone, this
line exhibited low level resistance to DDP, while dexa-
methasone had no effect on non-transfected cells. They found
that this effect was accompanied by a 40% decrease in DDP
accumulation as measured by '95Pt uptake and an increase in
the cellular metallothionein content.
DDP accumulation is also affected by a number of other
intracellular signaling mechanisms, including protein kinase
C (PKC), protein kinase A (PKA), and the Ca++/calmodulin
pathway. Mann et al. found that cyclic AMP-induced activa-
tion of PKA increased the cellular accumulation and toxicity
of DDP in drug sensitive human 2008 cells (Mann et al.,
1991). This effect was muted in the 2008/C13*5.25 DDP-
resistant daughter line. They found that 10 min DDP
accumulation could be doubled by treating the cells with
10O"M forskolin and tripled by treating with 1OJLM of the
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX). Curiously, when 1,9-dideoxyforskolin, an inactive
analog of forskolin, was used as a negative control, the
accumulation of DDP was decreased. These experiments
were repeated in another human ovarian carcinoma cell line,
A2780, with the same results, suggesting that the PKA path-
way mediates the uptake of DDP.
Howell et al. showed that the nucleoside transport
inhibitor dipyridamole increased DDP accumulation in 2008
cells in a dose-dependent manner (Howell et al., 1987;
Jekunen et al., 1992b). Dipyridamole (20pM) increased DDP
accumulation at 1 h by 2-fold. This concentration increased
DDP toxicity by 4.3-fold in these cells. Another inhibitor of
nucleoside transport, nitrobenzyl thioinosine did not have the
same effect, suggesting that inhibition of nucleoside transport
was not the mechanism of action. Although dipyridamole
inhibits cAMP phosphodiesterase in platelets, subsequent
work has shown that this effect was not mediated by increas-
ing intracellular levels of cAMP in 2008 cells (Jekunen et al.,
1992b).
Isonishi et al. demonstrated that phorbol esters were able
to sensitise 2008 cells to DDP. However, this effect was not
due to increased DDP accumulation (Isonishi et al., 1990).
Basu et al. confirmed the finding that increased PKC activity
sensitised cells to DDP. However, they found that this sen-
sitisation was accompanied by an increase in DDP accumula-
tion. They demonstrated that a 24 h pretreatment of HeLaREVIEW OF CELLULAR CISPLATIN ACCUMULATION 1173
cells with PKC activators such as TPA or PDBu increased
24h DDP accumulation by 200% (Basu et al., 1990). This
increase in accumulation at 24h was muted when protein
synthesis was inhibited by the addition of cycloheximide.
However, cycloheximide had no effect on uptake when the
phorbol ester pretreatment was only for an hour. It should
be noted that Basu et al. pretreated the cells with phorbol
esters, while Isonishi et al., treated the cells with phorbol
esters and DDP concurrently.
Kikuchi et al. studied the effects of blocking the Ca++/
calmodulin signal transduction pathway using the calmodulin
antagonists W-5 and W-7. They observed that the calmodulin
antagonists could potentiate the cytotoxicity of DDP in
human ovarian carcinoma cells. Measuring DDP accumula-
tion by atomic absorption spectroscopy, it was determined
that the mechanism by which the calmodulin antagonists
potentiated DDP toxicity was by increasing DDP accumula-
tion (Kikuchi et al., 1990). The uptake of DDP was slightly
increased by W-7 in the sensitive parental cell line. In the
resistant daughter cell line W-7 doubled the uptake in vitro
and tripled the uptake into a tumour in nude mice. At
present it is unclear how the calmodulin antagonists increase
the accumulation of DDP.
Other modulators of DDP accumulation
There are several things that affect DDP accumulation which
do not help discriminate between active transport vs passive
diffusion of DDP since they are compatible with both
theories of DDP transit into the cell. Andrews et al. showed
that the accumulation of DDP into 2008 cells was inversely
dependent on both extracellular pH and osmolality (Andrews
et al., 1987). Timmer-Bosscha et al. found that docosahexa-
enoic acid (DCHA) increased the toxicity of DDP in a
resistant subline of the human small cell lung carcinoma
GLC4, but not in the sensitive parental cell line (Timmer-
Bosscha et al., 1989). DCHA, a polyunsaturated fatty acid,
was able to increase DDP accumulation 300% at 4 h in the
resistant cell line as measured by atomic absorption.
The accumulation of DDP into cells is also temperature
dependent. Melvik and Pettersen have shown that NHIK
3025 cells at 22°C are 3-fold resistant to DDP as compared
to the same cells at 37'C. Using atomic absorption, they
determined that cells at 22°C needed three times the dose of
DDP to accumulate the same amount of platinum as they
did at 37°C (Melvik & Pettersen, 1988). Mann et al. also
found that cells at 22°C accumulate 3-fold less DDP than
those at 37°C. Using 2008 cells and a resistant subline Cl3/
5.25, they found that accumulation varied linearly with
temperature from 12°C to 40°C in both cell lines as deter-
mined by atomic absorption (Mann et al., 1988).
DDP accumulation can also be increased by permeabilisa-
tion of the plasma membrane. Melvik et al. demonstrated
that electropermeabilisation of the cell membrane during
DDP exposure increased sensitivity to DDP and that this was
mediated by a 3-fold increase in DDP accumulation as
measured by atomic absorption (Melvik et al., 1986).
Jekunen et al. demonstrated that uptake could be enhanced
by disrupting the cell membrane with heat or digitonin
(Jekunen et al., 1992a). Exposure to 20 LM digitonin in-
creased DDP accumulation 2-3-fold over control while
exposure to 65°C increased the uptake 4-7-fold.
Efflux of DDP
Although there have been a number of studies of the uptake
and accumulation of DDP, there has been relatively little
work reported on the efflux of DDP from cells. This is
unfortunate, since Melvik et al. reported data which suggests
that the plasma membrane is functioning as a barrier against
efflux as well as influx. They have shown that electro-
permeabilisation after DDP exposure protects NHIK 3025
cells from DDP toxicity, presumably by increasing DDP
efflux from the cells (Melvik et al., 1992). Mann et al.
measured the efflux of DDP from 2008 cells by atomic
absorption and found that the efflux was biphasic, with a
very rapid initial phase followed by a much slower terminal
phase (Mann et al., 1990). They also found that the initial
efflux was more rapid in the DDP-resistant variant of 2008
cells. Shionoya and Scanlon also found that efflux was
biphasic in K562 cells when measured by '95Pt-DDP reten-
tion; the initial efflux was complete in the first 5 min and the
remaining DDP was only very slowly effluxable (Shionoya &
Scanlon, 1986). Waud observed similar efflux kinetics in
L1210 cells as measured by 14C dichloro(ethylenediammine)
platinum retention (Waud, 1987). Neither Shionoya nor
Waud found increased efflux in the DDP-resistant variants of
their cell lines. Overall the existing data suggests that any
differences in efflux between sensitive and resistant cells are
of a smaller magnitude than the differences in influx,
although it should be emphasised that detailed studies of
efflux kinetics of DDP are lacking.
Working model of DDP accumulation
The current data paint a confusing picture of DDP
accumulation in the cell. On the one hand, DDP uptake
appears to occur by passive diffusion since it is not saturable
nor is it inhibited by structural analogs. On the other hand,
the uptake can clearly be modulated both by a variety of
pharmacologic agents that do not cause general permeabilisa-
tion of the membrane, and by activation of some intracellular
signal transduction pathways. An important observation is
that in no case has it been reported that uptake can be
inhibited by more than 50% of control.
One model that accommodates most of the existing obser-
vations envisions that approximately one half of the initial
drug uptake rate is due to passive diffusion and that the
other half is occurring by facilitated diffusion through a
gated channel (Figure 1). In such a system, one would not
expect to observe saturation of initial uptake since the rates
for both kinds of diffusion are a simple function of external
drug concentration. On the other hand, influx through such
channels is known to be influenced by many factors. In
addition, one would expect the change in accumulation
velocity with increasing temperature to be in the intermediate
range as has been observed for DDP (Mann et al., 1988).
Thus the model can explain each of the major arguments in
support of passive diffusion. At the same time, the model
accommodates the major arguments in favour of mediated
transport. If the channel is lost during selection of drug-
resistant variants, then one would expect up to a 50%
decrease in the initial rate of DDP uptake, even in the
absence of changes in the membrane fluidity. Information on
the regulation of a variety of gated channels makes it
reasonable to propose that flux through the channel is
regulated by phosphorylation cascades initiated by activation
of protein kinase A, protein kinase C, or by the calmodulin
dependent kinases. The ability of membrane impermeant
aldehydes to block 50% of the uptake suggests that critical
amino groups of the channel are exposed on the external
surface of the cell. The fact that ouabain inhibits 50% of the
initial uptake suggests that ion gradients maintained by this
ATPase are crucial to the function of this channel. This
hypothesis is further strengthened by the fact that proper
function of the channel is dependent upon maintenance of
the proper membrane potential. The model also provides a
reasonable explanation for why so many DDP-resistant sub-
lines exhibit decreased DDP accumulation as a phenotype. A
single base pair mutation in the transmembrane region of
such a protein would be sufficient to inhibit the channel's
function. Since DDP is a reasonably good mutagen in mam-
malian cells, the DDP selection itself could cause a loss of
function mutation. Conversely, a mutation that hyper-
polarises the cell, could keep the channel in the closed
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Figure 1 A working model of DDP accumulation. DDP can enter the cell either by way of passive diffusion or through a gated
channel. The flux through this channel can be increased by the agents on the right: docosahexaenoic acid (DCHA), dipyridamole,
l-propargyl-5-chloropyrimidin-2-one (NY 3170), calmodulin inhibitors (W-7), amphotericin B (AmB), and phosphorylation by
either PKA or PKC. The flux through the channel can be decreased by various aldehydes. The flux through this channel is also
dependent on a functional Na+/K+ ATPase, membrane potential, extracellular pH and extracellular osmolality.
Table I Agents that modulate DDP accumulation
Agents that increase accumulation
I-propargyl-5-chloropyrimidin-2-
one (Dornish et al., 1987)
Amphotericin B (Morikage etal.,
1991)
PKA activators (Mann etal.,
1991)
PKC activators (Basuet al.,1990)
Dipyridamole (Howell etal., 1987;
Jekunen etal., 1992b)
Calmodulin antagonists (Kirkuchi
etal., 1990)
Lowextracellular pH (Andrews
etal., 1987)
Lowextracellular osmolality
(Andrews etal., 1987)
High extracellularpotassium
(Andrews&Albright, 1991)
Docosahexaenoic Acid
(Timmer-Bosscha etal., 1989)
Agents thatdecreaseaccumulation
Aldehydes (Dornish etal., 1986;
Dornish etal., 1989)
Decreased intracellular ATP
(Andrews etal., 1988)
Ouabain (Andrews etal., 1988)
Low extracellular sodium
(Andrews etal., 1988)
c-Ha-ras(Isonishi etal., 1991)
Low extracellular potassium
(Andrews etal., 1991)
Based on this model, one would predict that analogs of
cisplatin that are substantially more lipophilic would not
exhibit decreased uptake in resistant cells and would
therefore have only limited cross-resistance. Presumably, such
lipophilic analogs would be less dependent on the gated
channel for entry into the cell. Kraker and Moore have
observed that in some DDP-resistant L1210 cells, there is no
cross-resistance to DACH-DDP (Kraker & Moore, 1988).
However, Nicolson et al. have shown considerable cross-
resistance in other L1210-derived resistant cells (Nicolson et
al., 1992). Using the more lipophilic ammine/amine platinum
(IV) dicarboxylates, Kelland et al. have been able to over-
come resistance in accumulation defective human 41McisR
cells. These drugs could not overcome resistance in the
CHlcisR cell line that had normal DDP accumulation. Al-
though they did not measure platinum accumulation in this
study, it is probable that these drugs were able to overcome
the accumulation defect in the 4lMcisR cells (Kelland et al.,
1992).
If wild-type cells contain a channel protein, and the
amount of this protein is altered in resistant cells with
decreased accumulation, then one might expect to be able to
develop antibodies differentially reactive with membrane pro-
teins of sensitive and resistant cells. In fact, Kawai et al. have
developed a rabbit polyclonal antibody raised against a
DDP-resistant murine lymphoma cell line which detects a
200 kD protein that is overexpressed in the resistant cells as
compared to the parental cell line (Kawai et al., 1990). The
amount of this 200 kD protein was inversely related to the
DDP accumulation in these cell lines. They have postulated
that this protein is analogous to p-glycoprotein. However it
is equally possible that this protein represents a non-
functional gated channel produced by the cell in excess
amounts in an effort to compensate for the loss of the
channel. Bernal et al. have developed a mouse monoclonal
antibody (SQM1) against a human squamous cell carcinoma
that is decreased in DDP and methotrexate resistant cells
(Bernal et al., 1991). The drug resistant variant expresses
only 20% of the SQM1 protein detectable in the parental cell
line as quantitated by indirect radioimmunoassay. Such a
decrease in SQM1 has been confirmed in the human small
cell carcinoma, SW2-S. The gene encoding SQM1 has been
cloned and predicts a protein of 135 amino acids. This
protein does not have a recognisable transmembrane region,
however it does appear to have a secretory leader sequence.
Bernal et al. have postulated that SQM1 is an extracellular
protein that interacts with membrane spanning proteins to
facilitate DDP and methotrexate transport into the cells.
In conclusion, DDP enters the cell through a process
which although not saturable, is able to be modulated by a
variety of agents. While the discovery that one can modulate
uptake is leading to the development of new therapeutic
strategies, since decreased accumulation is a common feature
of DDP resistance, additional information on the
mechanisms of uptake is urgently needed. Although the cel-
lular control of DDP accumulation is undoubtedly more
complicated than described in this model, and quite probably
varies in different cell lines, the major virtue of this model is
that it permits the design of specific experiments to further
define the mechanisms of DDP entry into cells.
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diaminocyclohexaneplatinum sulfate; cAMP, cyclic adenosine
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